FSBI National Medical Research Center of Hematology of the Ministry of Health of Russia Hematological Research Center
Content |
Owners
History
2025: The first launch of CAR-T-cell product production in Russia
The National Medical Research Center of Hematology Ministry of Health Russia was the first medical institution in the country to receive a full set of licenses for the production of CAR-T-cell products for the treatment of oncohematological diseases. Roszdravnadzor issued a license to the center for the production of biomedical cell products, including individual drugs for the therapy of blood malignancies. This became known on July 22, 2025.
The National Medical Research Center of Hematology received two key licenses - from the Ministry of Industry and Trade of Russia in September 2024 and from Roszdravnadzor in June 2025. The combination of permits allows the center to carry out a full cycle of development and production of innovative cell drugs.
Apollinaria Bogolyubova-Kuznetsova, Head of the Department of Biomedical Technologies, Head of the Laboratory of Translational Immunology at the National Medical Research Center of Hematology, emphasized the importance of obtaining licenses for the treatment of patients within the framework of the entire diversity of Russian legal regulation.
Bogolyubova-Kuznetsova noted that new opportunities are especially important for patients in need of hospital exclusion treatment within the framework of individual medical use. This is not only about an anti-CD19 CAR-T cell drug, but also about the entire spectrum of cell drugs for use under the new license.
Dinara Barakova, head of the technological control department of the National Medical Research Center of Hematology, explained that the issuance of the license by Roszdravnadzor confirms the compliance of production facilities and the center's documentation with the requirements for the production of biomedical cell products.
The license allows for wider application of the CAR-T cell product, including use within the hospital exemption. This legal mechanism allows the use of unregistered treatments in exceptional cases when the patient has exhausted standard therapy options.[1]
2024: Russian Prime Minister Mikhail Mishustin allocated 82.3 million rubles for the purchase of medical equipment
On September 11, 2024, Russian Prime Minister Mikhail Mishustin signed a decree on the allocation of a subsidy of ₽82,3 million to the National Medical Research Center for Hematology (NMIC Hematology) of the Russian Ministry of Health to strengthen the material and technical base of the institution. These funds will be used for the purchase and commissioning of at least 39 units of modern medical equipment in 2024. The funding will be from the government's reserve fund.
The purpose of this subsidy is to improve the conditions for the development and production of high-tech drugs, which meets the tasks set in the Strategy for the Development of the Pharmaceutical Industry until 2030. The strategy is aimed at providing the Russian market with domestic drugs, including innovative drugs necessary for the treatment of complex diseases, such as oncohematological pathologies.
According to the "Government of the Russian Federation," the Ministry of Health of Russia is entrusted with strict control over the targeted and effective use of the allocated funds. The agency is obliged to submit a report on the results of the program by February 1, 2025. The project will purchase equipment for the further development of drugs, such as CAR-T therapy, which has already shown its effectiveness in preclinical trials and may become important in the treatment of B-cell malignancies.
Within the framework of this program, the National Medical Research Center of Hematology plans to significantly expand its production, as well as improve access to innovative therapies. The introduction of new equipment will allow the center not only to increase production volumes, but also to reduce dependence on imports, which is important in the context of current challenges in the field. health care[2]
2021: Opening of a new operating unit for 120 million rubles
In early June 2021, it became known Ministry of Health Russia that a new operational unit was opened at the Federal State Budgetary Institution of National Medical Research Center of Hematology, created as a result of a project worth 120 million. rubles The funds were received in the form of subsidies from the federal budget.
Two new operating rooms with auxiliary rooms with a total area of 131.5 square meters. m are designed using a climate module for clean rooms. Finishing of walls and ceilings is made of steel plates. All requirements for modern operational requirements are taken into account: resistance to mold formation, exposure to chemicals, absence of glare on the surface, etc. Certified medical equipment manufactured in Germany, France and China was purchased.
The modernization of the premises of the operational unit began at the end of 2019. The construction part was agreed through the Glavgosexpertiza of Russia and the Ministry of Health of the Russian Federation.
 | When this building was built, it was not assumed that the clinic would have such a scale. Then there were only four departments, a total of about 200 beds. The need for operations has grown significantly. Now new operating rooms equipped with modern high-tech equipment will significantly increase the volume and variety of surgical interventions, "said Alexander Grzhimolovsky, head of the operational unit of the National Medical Research Center of Hematology, whose words are quoted by the press service of the Ministry of Health. |  |
By the beginning of June 2021, the operational unit of the National Medical Research Center of Hematology is an independent unit that ensures the work of the departments of the Center for Surgical Orientation:
- scientific and clinical department of hematological surgery;
- scientific and clinical department of hematological orthopedics;
- departments of reconstructive and restorative orthopedics for patients with hemophilia;
- scientific and clinical department of hemodialysis and multiple organ pathology.[3]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |